Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase

PEG-modified recombinant mammalian urate oxidase (PEG-uricase) is being developed as a treatment for patients with chronic gout who are intolerant of, or refractory to, available therapy for controlling hyperuricemia. In an open-label phase I trial, single subcutaneous injections of PEG-uricase (4 t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ganson, Nancy J, Kelly, Susan J, Scarlett, Edna, Sundy, John S, Hershfield, Michael S
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1526556/
https://www.ncbi.nlm.nih.gov/pubmed/16356199
http://dx.doi.org/10.1186/ar1861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1526556/
https://www.ncbi.nlm.nih.gov/pubmed/16356199
http://dx.doi.org/10.1186/ar1861

Ejemplares similares